<DOC>
	<DOCNO>NCT02171286</DOCNO>
	<brief_summary>The BCCA Oncopanel clinical assay develop determine genotype status prospectively define set gene . The purpose pilot study assess feasibility effect clinical-decision-making Oncopanel test . Eligible patient advance lung , colorectal , melanoma GIST cancer patient diagnose malignancy consider clinical trial .</brief_summary>
	<brief_title>The Oncopanel Pilot ( TOP ) Study</brief_title>
	<detailed_description>Somatic mutation solid tumor represent establish mean characterize malignancy prognostic , diagnostic therapeutic purpose . Mutations EGFR , KRAS , BRAF , KIT PDGFRA gene direct therapy patient advance lung , colorectal , melanoma , GIST tumor , respectively . Known novel mutation gene may also clinical significance identify current genotyping offer BC Cancer Agency ( BCCA ) patient . Furthermore , numerous candidate gene implicate potential prognostic predictive biomarkers patient solid tumour . As , Oncopanel clinical assay develop determine genotype status prospectively define set gene . The follow clinically relevant set gene exon include Oncpanel : KRAS , EGFR , BRAF , NRAS HRAS , PIK3CA Signal Transduction Pathway Genes , RAS-RAF-MEK-MAPK Pathway , HER2 , IDH1 IDH2 , ALK , TP53 , c-KIT , STAT1 &amp; 3 PDGFRA . Additional test tumour material also include analysis specific gene variant associated adverse event response therapy . Numerous study document presence circulate tumour DNA ( ctDNA ) among patient advance early stage malignancy ( 20-22 ) . The ability diagnose standard cancer mutation blood-based assay ( `` liquid biopsy '' ) yet establish present obvious advantage . The emergence `` resistance '' mutation arise metastatic tumor throughout course therapy well document ( 21 , 22 ) . A blood biopsy may represent accurate determination tumor 's genetic feature archival DNA specimen . Adequate tissue specimens difficult obtain patient diagnosed malignancy , particularly lung cancer . A blood biopsy may represent less invasive timelier mean diagnose standard translational cancer mutation .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Patients archival tumor tissue know history invasive malignancy eligible meet one follow criterion : Advanced colorectal cancer eligible standard KRAS testing , Advanced nonsmall cell lung cancer eligible standard EGFR testing , Advanced melanoma eligible standard BRAF testing , Gastrointestinal stromal tumor ( GISTs ) eligible standard cKIT PDGFRA testing , Being consider potential eligibility clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>KRAS</keyword>
	<keyword>EGFR</keyword>
	<keyword>BRAF</keyword>
	<keyword>NRAS HRAS</keyword>
	<keyword>PIK3CA</keyword>
	<keyword>RAS-RAF-MEK-MAPK</keyword>
	<keyword>HER2</keyword>
	<keyword>IDH1 IDH2</keyword>
	<keyword>ALK</keyword>
	<keyword>TP53</keyword>
	<keyword>c-KIT</keyword>
	<keyword>STAT1 &amp; 3</keyword>
	<keyword>PDGFRA</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Advanced non-small cell lung cancer</keyword>
	<keyword>Advanced melanoma</keyword>
	<keyword>Gastrointestingal Struma Tumor</keyword>
	<keyword>Candidate gene implicate potential prognostic predictive biomarkers patient solid tumour</keyword>
	<keyword>Circulating Tumor DNA</keyword>
</DOC>